Phase 3 Clinical Trials With Primary Completion Dates in October 2020
This is a list of Phase 3 trials with primary completion dates in October 2020 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.
The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.
|Symbol||Company||Primary Completion Date||Phase||NCT ID||Title|
|BBI||Brickell Biotech, Inc.||2020-10-01||Phase 3||NCT03948646||Safety and Efficacy Study of Sofpironium Bromide in Subjects With Axillary Hyperhidrosis (BBI-4000-CL-302)|
|BBI||Brickell Biotech, Inc.||2020-10-01||Phase 3||NCT03836287||Safety and Efficacy Study of Sofpironium Bromide in Subjects With Axillary Hyperhidrosis (BBI-4000-CL-301)|
|BCLI||Brainstorm Cell Therapeutics Inc.||2020-10-01||Phase 3||NCT03280056||Safety and Efficacy of Repeated Administrations of NurOwnÂ® in ALS Patients|
|GNFT||Genfit SA||2020-10-01||Phase 3||NCT02704403||Phase 3 Study to Evaluate the Efficacy and Safety of Elafibranor Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH)|
|GRTX||Galera Therapeutics, Inc.||2020-10-01||Phase 3||NCT03689712||ROMAN: A Study to Investigate the Effects of GC4419 on Radiation Induced Oral Mucositis in Patients With Head/Neck Cancer|
|RETA||Reata Pharmaceuticals, Inc.||2020-10-01||Phase 3||NCT03068130||Extended Access Program to Assess Long-term Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension RANGER|
|TNXP||Tonix Pharmaceuticals Holding Corp.||2020-10-01||Phase 3||NCT04172831||A Study To Evaluate The Efficacy And Safety Of TNX-102 SL In Patients With Fibromyalgia|